# Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

> **NCT06525766** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 35 (estimated)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen-receptor-positive Breast Cancer
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Breast Cancer

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Capecitabine
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06525766
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2030-10-15
- **Final completion:** 2030-10-15
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525766, "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT06525766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*